Janux Therapeutics vs Prelude Therapeutics
Prelude Therapeutics is the larger business, with $12.1m of revenue in fiscal 2025 against $10.0m for Janux Therapeutics (1.2 times as much). Prelude Therapeutics grew faster (73.4% against -5.6%). Prelude Therapeutics kept more of each dollar of sales as profit: a net margin of -819.6% against -1136.3%. Janux Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Janux TherapeuticsJANX, 2025 | Prelude TherapeuticsPRLD, 2025 |
|---|---|---|
| Revenue | $10.0m | $12.1m |
| Revenue growth | -5.6% | 73.4% |
| Net income | −$114m | −$99.5m |
| Operating margin | -1576.7% | -861.3% |
| Net margin | -1136.3% | -819.6% |
| Return on equity | -11.5% | -99.5% |
| Free cash flow | −$83.3m | −$56.4m |
| Cash | $52.3m | $35.3m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 109 | 79 |
| Market value | $1.08bn | $372m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 0 buys, 11 sales | 4 buys, 0 sales |